BioAtla Investor Presentation Deck

Summary of Dosing Regimens for Phase 2 Clinical Studies with CAB-AXL-ADC BA3011 Mecbotamab Vedotin Indication Soft tissue and bone sarcoma LMS UPS NSCLC Ovarian* bicatla Dose Q2W monotherapy and combo w/ nivolumab 3Q4W monotherapy 2Q3W monotherapy 3Q4W monotherapy Q2W monotherapy Q2W in combo w/ nivolumab 2Q3W monotherapy 3Q4W monotherapy Q2W in combo w/ durvalumab *Investigator-initiated trial. LMS, leiomyosarcoma; UPS, undifferentiated pleomorphic sarcoma; NSCLC, non small cell lung cancer. Maximum Patient # ~15 per cohort N~ 15 N~ 20 N~ 20 N~ 20 N~ 20 N~ 20 N~ 20 N~ 20 BioAtla| Overview 23

View entire presentation